…
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | 29160.00M | 21630.00M | 23686.30M | 36835.00M | 26660.40M |
| Minority interest | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net income | 21910.00M | 16000.00M | 18240.00M | 29604.50M | 19842.90M |
| Selling general administrative | 1430.00M | 1250.00M | 1260.00M | 1085.90M | 831.40M |
| Selling and marketing expenses | 1360.00M | 900.00M | 1140.00M | 1270.10M | 1240.30M |
| Gross profit | 31910.00M | 45270.00M | 44870.00M | 57073.50M | 45342.60M |
| Reconciled depreciation | 4020.00M | 3780.00M | 3431.80M | 3115.10M | 2555.90M |
| Ebit | 29190.00M | 21650.00M | 23705.90M | 36854.90M | 26681.30M |
| Ebitda | 33210.00M | 25430.00M | 27137.70M | 39970.00M | 29237.20M |
| Depreciation and amortization | 4020.00M | 3780.00M | 3431.80M | 3115.10M | 2555.90M |
| Operating income | 26380.00M | 19520.00M | 20622.10M | 35737.70M | 26159.90M |
| Other operating expenses | 67200.00M | 59640.00M | 56866.00M | 52254.60M | 42423.50M |
| Interest expense | 30.00M | 30.00M | 19.60M | 19.90M | 20.90M |
| Tax provision | 7250.00M | 5630.00M | 5452.50M | 7230.50M | 6817.50M |
| Interest income | 3480.00M | 3010.00M | 3389.70M | 8.00M | 52.50M |
| Net interest income | -20.00M | -30.00M | -6.70M | -8.00M | -8.70M |
| Income tax expense | 7250.00M | 5630.00M | 5452.50M | 7230.50M | 6817.50M |
| Total revenue | 93580.00M | 77960.00M | 77488.10M | 87992.30M | 68583.40M |
| Total operating expenses | 5530.00M | 4610.00M | 4914.10M | 21335.80M | 19182.70M |
| Cost of revenue | 61670.00M | 32690.00M | 51951.90M | 30918.80M | 23240.80M |
| Total other income expense net | 2780.00M | 2110.00M | 3064.20M | 1097.30M | 500.50M |
| Net income from continuing ops | 21910.00M | 16000.00M | 18233.80M | 29604.50M | 19842.90M |
| Net income applicable to common shares | 21910.00M | 16000.00M | 18233.80M | 29604.50M | 19842.90M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 169470.00M | 154700.00M | 144387.70M | 133747.10M | 107740.70M |
| Intangible assets | 40.00M | 40.00M | 52.80M | 74.90M | 49.50M |
| Other current assets | 650.00M | 6320.00M | 2017.70M | 2175.50M | 1531.90M |
| Total liab | 19780.00M | 18990.00M | 16716.80M | 16465.30M | 14794.60M |
| Total stockholder equity | 149690.00M | 135710.00M | 127670.90M | 117281.80M | 92946.10M |
| Other current liab | 5000.00M | 8950.00M | 2875.60M | 3990.30M | -47.20M |
| Common stock | 530.00M | 530.00M | 530.90M | 530.90M | 530.90M |
| Capital stock | 530.00M | 530.00M | 530.90M | 530.90M | 530.90M |
| Retained earnings | 134000.00M | 117860.00M | 109581.10M | 99888.50M | 75977.20M |
| Other liab | - | - | - | 4481.10M | 3633.10M |
| Other assets | 750.00M | 680.00M | 956.70M | 1562.20M | 1848.60M |
| Cash | 4320.00M | 3630.00M | 1697.00M | 12147.60M | 20303.20M |
| Cash and equivalents | 3940.00M | 3400.00M | 1407.70M | 11928.80M | 20085.20M |
| Total current liabilities | 14520.00M | 12780.00M | 11010.80M | 11955.50M | 11124.60M |
| Current deferred revenue | 400.00M | 340.00M | 505.20M | - | 3528.40M |
| Net debt | -4280.00M | -3600.00M | -1664.40M | -12110.70M | -20254.90M |
| Short term debt | 20.00M | 20.00M | 4.90M | 8.20M | 11.40M |
| Short long term debt | 20.00M | 0.00M | 0.00M | 0.00M | 3.50M |
| Short long term debt total | 40.00M | 30.00M | 32.60M | 36.90M | 48.30M |
| Other stockholder equity | 800.00M | 17060.00M | 17558.90M | 16862.40M | 16438.00M |
| Property plant equipment | 64600.00M | 55130.00M | 49292.00M | 47874.90M | 44095.40M |
| Total current assets | 100810.00M | 96750.00M | 93117.40M | 83515.00M | 61747.10M |
| Net tangible assets | - | - | - | 117206.90M | 92896.60M |
| Short term investments | 31240.00M | 33380.00M | 40494.60M | 15270.10M | 546.40M |
| Net receivables | 29780.00M | 21580.00M | 18904.00M | 25635.60M | 17913.30M |
| Inventory | 33230.00M | 31840.00M | 30004.10M | 28286.20M | 21452.30M |
| Accounts payable | 9100.00M | 8240.00M | 7625.10M | 7957.00M | 7632.00M |
| Accumulated other comprehensive income | 14360.00M | 260.00M | - | - | - |
| Non currrent assets other | 640.00M | 1660.00M | 40996.30M | 16930.10M | 2348.20M |
| Non current assets total | 68660.00M | 57950.00M | 51270.30M | 50232.10M | 45993.60M |
| Capital lease obligations | 20.00M | 30.00M | 32.60M | 36.90M | 44.80M |
| Long term debt total | 20.00M | 20.00M | 27.70M | 28.70M | 36.90M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | -8040.00M | -2690.00M | -27076.20M | -15485.30M | 9281.60M |
| Change to liabilities | - | - | 0.00M | 342.70M | 1748.00M |
| Total cashflows from investing activities | -10990.00M | -2690.00M | -27076.20M | -21949.20M | 751.30M |
| Net borrowings | - | - | - | -11.40M | -340.20M |
| Total cash from financing activities | -7970.00M | -7990.00M | -7971.70M | -5324.40M | -348.90M |
| Change to operating activities | - | - | - | 202.90M | 1078.90M |
| Net income | 21910.00M | 16000.00M | 23686.30M | 36835.00M | 26660.40M |
| Change in cash | 610.00M | 1930.00M | -10450.60M | -8155.60M | 19871.70M |
| Begin period cash flow | 3710.00M | 1700.00M | 12147.60M | 20303.20M | 431.50M |
| End period cash flow | 4320.00M | 3630.00M | 1697.00M | 12147.60M | 20303.20M |
| Total cash from operating activities | 19460.00M | 12610.00M | 24597.30M | 19118.00M | 19469.30M |
| Depreciation | 4020.00M | 3780.00M | 3431.80M | 3115.10M | 2555.90M |
| Other cashflows from investing activities | 35410.00M | 3000.00M | -22346.00M | 668.10M | 570.10M |
| Dividends paid | -7960.00M | -7960.00M | 7964.10M | 5309.40M | 5309.40M |
| Change to inventory | -520.00M | -1840.00M | -1717.90M | -6833.90M | -2813.70M |
| Change to account receivables | -5820.00M | -3610.00M | 6504.10M | -7416.20M | -2653.10M |
| Other cashflows from financing activities | -10.00M | -20.00M | -7.60M | -15.00M | -16.10M |
| Change to netincome | - | - | - | 102.90M | -288.70M |
| Capital expenditures | 14380.00M | 10030.00M | 4730.20M | 7132.00M | 9101.90M |
| Change in working capital | -5540.00M | -6070.00M | 4188.10M | -13704.50M | -2640.80M |
| Other non cash items | -930.00M | -1100.00M | -6708.90M | -7127.60M | -7106.20M |
| Free cash flow | 5080.00M | 2580.00M | 19867.10M | 11986.00M | 10367.40M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(INR) |
Price
(INR) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories Limited |
83.00 0.73% |
11450.00 | 70.47 | - | 17.47 | 11.44 | 17.33 | 47.08 |
| SUNPHARMA Sun Pharmaceutical Industries Limited |
-12.10 0.64% |
1890.20 | 40.32 | 26.95 | 7.69 | 5.50 | 7.41 | 23.64 |
| TORNTPHARM Torrent Pharmaceuticals Limited |
-60.90 1.28% |
4700.10 | 63.48 | 56.50 | 11.13 | 16.39 | 11.65 | 35.91 |
| CIPLA Cipla Limited |
-15.90 1.12% |
1404.00 | 21.74 | 19.01 | 4.23 | 3.76 | 4.08 | 14.00 |
| DRREDDY Dr. Reddy's Laboratories Limited |
11.00 0.80% |
1388.00 | 17.16 | 21.93 | 2.94 | 2.89 | 2.99 | 10.39 |
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
| Name | Title | Year Born |
|---|---|---|
| Dr. Kiran Satchandra Divi B. Pharm., M.Pharm | CEO & Whole-Time Director | 1976 |
| Mr. L. Kishore Babu B.Com, FCMA, FICWA | Chief Financial Officer | 1952 |
| Mr. L. Ramesh Babu LLB, M.Com, MBA | VP of Procurement & Chief Information Officer | 1957 |
| Mr. M. Satish Choudhury | Company Sec. & Compliance Officer | NA |
| Mr. Venkata Ramana Nimmagadda B.Sc.(Chem) | Exec. Director | 1958 |
| Dr. Murali Krishna Prasad Divi M. Pharm, Ph.D. | MD & Exec. Director | 1951 |
| Mr. Madhusudana Rao Divi | Director of Projects & Whole-Time Director | 1944 |
| Mr. M. Ramesh Babu B.Sc. | Chief Technologist | 1966 |
| Mr. P. Srinivasa Rao M.Pharm | Chief Technologist | 1965 |
| Ms. Nilima Prasad Divi | Whole-time Director & Director of Commercial | 1982 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.